ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

11:30AM-1:00PM: Abstract Number: 0433

Racial Disparities and New SLE-Specific Predictors of Stroke and Ischemic Heart Disease in Patients with Lupus

Plenary Session I (0429–0433)

11:30AM-1:00PM: Abstract Number: 0432

The Effect on Renal Function of the Complement C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

Plenary Session I (0429–0433)

3:00PM-3:50PM: Abstract Number: 0483

Can a Clinical Disease Activity Index Based on Patient-Reported Joint Counts (PT-CDAI) Be Used to Inform Target-Based Care in Telemedicine? An Analysis of 2 Early RA Cohort Studies

RA – Diagnosis, Manifestations, & Outcomes I: Pre-Onset & Early RA (0479–0483)

3:00PM-3:50PM: Abstract Number: 0509

Classification of Patients with Relapsing Polychondritis Based on Somatic Mutations in UBA1

Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA, Behçet’s, & Relapsing Polychondritis (0509–0513)

3:00PM-3:50PM: Abstract Number: 0507

Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Psoriatic Arthritis (0504–0508)

3:00PM-3:50PM: Abstract Number: 0449

Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca

Immunological Complications of Therapy (0449–0453)

3:00PM-3:50PM: Abstract Number: 0482

Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort

RA – Diagnosis, Manifestations, & Outcomes I: Pre-Onset & Early RA (0479–0483)

3:00PM-3:50PM: Abstract Number: 0479

Early DAS Response After DMARD-start Increases Probability of Achieving Sustained DMARD-free Remission in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes I: Pre-Onset & Early RA (0479–0483)

3:00PM-3:50PM: Abstract Number: 0506

Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Psoriatic Arthritis (0504–0508)

3:00PM-3:50PM: Abstract Number: 0504

Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial

Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Psoriatic Arthritis (0504–0508)

3:00PM-3:50PM: Abstract Number: 0512

Efficacy of Apremilast for the Treatment of Manifestations of Behçet’s Syndrome Other Than Oral Ulcers, Including Skin Lesions and Arthritis

Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA, Behçet’s, & Relapsing Polychondritis (0509–0513)

3:00PM-3:50PM: Abstract Number: 0511

ERAP1-mediated Immunogenicity and Immune-phenotypes in HLA-B51+ Behçet’s Disease Point to Pathogenic CD8 T Cell Effector Responses

Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA, Behçet’s, & Relapsing Polychondritis (0509–0513)

3:00PM-3:50PM: Abstract Number: 0510

Expression and Functional Activity of the Angiotensin II System in Temporal Artery Lesions from Patients with Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA, Behçet’s, & Relapsing Polychondritis (0509–0513)

3:00PM-3:50PM: Abstract Number: 0480

Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort

RA – Diagnosis, Manifestations, & Outcomes I: Pre-Onset & Early RA (0479–0483)

3:00PM-3:50PM: Abstract Number: 0450

In Vitro Characterization of Inflammatory Arthritis Associated with Immune Check Point Inhibition

Immunological Complications of Therapy (0449–0453)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].